Colonic PolypCADxNCT06062095
Computer Aided Diagnosis (CADx) for Colorectal Polyps Resect-and-Discard Strategy
A study testing AI-powered computer-aided diagnosis (CADx) in people with Colonic Polyp, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
Colonoscopic removal of adenomatous polyps reduce both the incidence and mortality of colorectal cancer (CRC). The common clinical management of colorectal polyp detected during colonoscopy is to remove them and send for histopathology to determine the subsequent surveillance interval. Read more about this study
- Who is it for?
- Ages 40 to 90 years
- Conditions the study is for
- Colonic Polyp
- What is being tested?
- AI-powered computer-aided diagnosis (CADx)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,764 participants
- Where
- 1 siteHong Kong
- Study dates
- 29 Sep 2023to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- undergoing elective colonoscopy with any indication (screening, surveillance or diagnostic) and complete colonoscopy (caecal intubation) with at least one colorectal polyp detected will be recruited
Who cannot join
- personal history of CRC or inflammatory bowel disease, prior colorectal surgery, receiving anticoagulant therapy
- lack of informed consent
Trial locations and contacts
1 site in 1 country.
Hong Kong1 site
Combined Endoscopy Unit, ALice Ho Miu Ling Nethersole Hospital
Hong Kong
About this study
Official title: Computer Aided Diagnosis (CADx) for Colorectal Polyps Resect-and-Discard Strategy: a Multi-centre Randomized Controlled Trial
Colonoscopic removal of adenomatous polyps reduce both the incidence and mortality of colorectal cancer (CRC). The common clinical management of colorectal polyp detected during colonoscopy is to remove them and send for histopathology to determine the subsequent surveillance interval. More than 80% of polyps detected during screening or surveillance colonoscopy are diminutive (≤5mm). As the chance of diminutive polyps to harbor cancer or advanced neoplasia is low, leave-in-situ and resect-and-discard strategies using optical diagnosis are recommended for non-neoplastic polyps by the American Society for Gastrointestinal Endoscopy (ASGE) and the European Society for Gastrointestinal Endoscopy (ESGE) so as to reduce the financial burden of polypectomy and histopathology. The societies proposed leave-in-situ strategy if optical diagnosis can achieve a negative predictive value (NPV) of >90% for rectosigmoid polyp and resect-and-discard if an agreement of more than 90% concordance with histopathology-based post-polypectomy surveillance interval can be achieved. However, optical diagnosis is operator dependent and most endoscopists are reluctant to adopt this strategy in routine practice because of the need of strict training and auditing and fear of incorrect diagnosis.
In the past decade, with the exponential increase in computational power, reduced cost of data storage, improved algorithmic sophistication, and increased availability of electronic health data, artificial intelligence (AI) assisted technologies were widely adopted in various healthcare settings to improve clinical outcomes, especially the quality of colonoscopy in the area of gastroenterology. Real time use of computer-aided diagnosis (CADx) for adenoma using AI systems were developed and proven to be useful to help endoscopists to distinguish neoplastic polyps from non-adenomatous polyps. However, these studies only examined diminutive polyp but not polyp of larger size (>5mm). They were conducted with small sample size of less than few hundred subjects and the study settings were open-label and non-randomized.
The investigators aim to conduct a large scale randomized controlled trial to evaluate the performance of colorectal polyp characterization of all size polyps by real-time CADx using AI system against conventional colonoscopy with optical diagnosis.
Read the detailed description
Study setting
This is an international, prospective, multi-centre, single-blind, non-inferiority, randomized controlled trial conducted in 6 university-affiliated endoscopy centres China (4 centres), Hong Kong and Singapore. This study will be conducted according to the CONSORT-AI and SPIRIT-AI guideline and complied with ICH-GCP and the declaration of Helsinki.
Artificial intelligence polyp characterization system
The investigators refer to the NICE (Narrow Band Imaging International Colorectal Endoscopic) classification as the standard to establish a deep neural network model for polyp type differentiation. To build the polyp characterization model, the investigators collected 3762 images of polyps under NBI for model training and testing, including 1483 cases of hyperplastic polyps, 1993 cases of adenomas and 286 cases of advanced tumors.
The difference of image features among the three types of NICE classification is obvious, and it is easy to distinguish them by computer under endoscope. Considering the processing capacity of the computer hardware equipped with the model, in order to achieve real-time analysis under limited computing resources, the investigators chose a lightweight network architecture called Mobile-Net to build the model. In a Mobile-Net framework, the first is a 3x3 standard convolution layer, followed by a heap of depth-wise separable convolution layers. Some of the depth-wise convolution layers will be down sampled through streets set as 2. The following average pooling layer changes the features to 1x1. According to the predicted category size, a full connection layer is then added, and finally a soft-max layer is added. If the depth-wise convolution layers and point-wise convolution layers are calculated separately, the entire network has only 28 layers ( Avg Pool and Softmax are not included). At present, the model has not been clinically validated. The investigators used a five-fold cross validation to evaluate the accuracy of the model. The results showed that the classification accuracy of the model in the current dataset exceeds 99%
Standardized training of optical diagnosis
Before the initiation of the study, participating endoscopists will be given a standardized online training workshop on the operation of the AI polyp characterization system, principles of optical diagnosis and an image-based quiz.
Colonoscopy procedures
Study colonoscopies will be performed by 12 non-expert endoscopists (colonoscopy experience <2000) and 12 expert endoscopists (colonoscopy experience ≥2000), with 2 non-expert and 2 expert endoscopists from each of the 6 centres. All colonoscopies will be performed by using high-definition endoscopy system and colonoscope (EVIS Lucera Elite, 290 series, Olympus, Co Ltd, Tokyo, Japan). All enrolled patients received low-fiber diets 3 days prior to colonoscopy and underwent bowel cleansing with polyethylene glycol solution in split dose based on institutional protocol. Colonoscopies will be performed under conscious sedation. Bowel preparation quality will be rated by the Boston Bowel Preparation Scale (BBPS) with adequate bowel preparation being defined as BBPS score ≥6 and any segmental BBPS score ≥2.
For patients randomized to the conventional colonoscopy (CC) with optical diagnosis group, the endoscopists will turn on narrow band imaging (NBI) mode once a polyp is detected. An optical diagnosis will be provided without magnification. Hyperplastic and sessile serrated polyps are categorized as non-neoplastic, adenoma and malignancy as neoplastic. The diagnosis will be recorded with the level of confidence of the assessment (high or low). For patients randomized to the AI-powered CADx colonoscopy (AI) group, endoscopists will turn on CADx upon detection of colorectal polyp. The polyp will then be marked by a blue tracking box and shown on the same high-definition monitor of the endoscopy system. The AI will provide a diagnosis (non-neoplastic or neoplastic) next to the tracking box. For the purpose of this study, all polyps irrespective of optical or AI diagnosis will be removed by endoscopic polypectomy/endoscopic mucosal resection (EMR)/endoscopic submucosal dissection (ESD) during withdrawal phrase and send for histopathology. Endoscopists are not allowed to leave any identified polyp in-situ at their discretion.
Location, size and morphology of all removed polyps will be documented. Proximal colon is defined as segment from cecum to transverse colon, while distal colon is defined as segment from splenic flexure to rectum. Polyps will be classified into pedunculated or non-pedunculated morphology and non-pedunculated lesions will be further characterized as sessile, flat or depressed lesions. Polyps removed will be placed in separate specimen bottles. Colonic polyp specimens will be evaluated by pathologists of individual study centre who are blinded to study group assignment. Colonic polyp specimens will be evaluated according to the 2019 WHO classification of tumours of the digestive system. Advanced adenomas are defined as adenomas with size ≥10mm, villous component, or high-grade dysplasia. Diagnostic yield of any existing colonic pathology will not be comprised if the subject is allocated to the AI group. Patients will be monitored for any immediate adverse event post colonoscopy and will be discharged after recovery from sedation.
- Conditions
- Colonic Polyp
- Being tested
- AI-powered computer-aided diagnosis (CADx)
- Medical subject headings
- Colonic Polyps
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-powered computer-aided diagnosis (CADx)Procedure or surgery
Real time AI will be used to diagnosis polyps found during colonoscopy.
| Study group | Role | What they receive |
|---|---|---|
| AI arm | Experimental | AI will be used to diagnose polyps Receives: Procedure: AI-powered computer-aided diagnosis (CADx) |
| Control arm | No intervention | Conventional colonoscopy without AI will be perform to diagnose polyps |
What is being measured
The primary outcome is the main question the study is designed to answer.
diagnostic accuracy of polyp histology in %
the NICE classification (NICE I: non-neoplastic polyp: NICE II: adenoma; NICE III: invasive tumor) given by the AI CADx and conventional optical diagnosis will be compared against the polyp histopathology (reference standard)
Measured: 24 months
Secondary outcomes (5)
sensitivity (%)
sensitivity to correctly predict polyp histopathology polyps.
Measured: 24 months
specificity (%)
specificity to correctly predict polyp histopathology polyps
Measured: 24 months
positive predictive value (%)
positive predictive value to correctly predict polyp histopathology polyps
Measured: 24 months
negative predictive value (%)
negative predictive value to correctly predict polyp histopathology polyps
Measured: 24 months
agreement in assigning post-polypectomy surveillance intervals with pathology-based diagnoses (%)
agreement in assigning post-polypectomy surveillance intervals with pathology-based diagnoses according to the latest USMSTF, ESGE and Asia-Pacific guidelines
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2023
- Study start29 Sep 2023
- Primary completion30 Nov 2025
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colonic PolypStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 1,764 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Collaborators
- Nanyang Technological University, The First Hospital of Jilin University, Shenzhen Hospital of Southern Medical University, Jiangsu Province Hospital of Traditional Chinese Medicine, Jiangsu Taizhou People's Hospital
- Responsible party
- Principal investigator, Thomas Yuen Tung Lam, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06062095
- Sponsor's protocol ID
- 2022.525
- Acronym
- CADx
- Status last verified
- Apr 2026
- First submitted
- 6 Sep 2023
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Computer Aided Diagnosis (CADx) for Colorectal Polyps Resect-and-Discard Strategy: a Multi-centre Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06062095
- Acronym / sponsor ID
- CADx / 2022.525
- Conditions
- Colonic Polyp
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,764 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Collaborators
- Nanyang Technological University, The First Hospital of Jilin University, Shenzhen Hospital of Southern Medical University, Jiangsu Province Hospital of Traditional Chinese Medicine, Jiangsu Taizhou People's Hospital
- Study start
- 29 Sep 2023 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 2 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Colonoscopic removal of adenomatous polyps reduce both the incidence and mortality of colorectal cancer (CRC). The common clinical management of colorectal polyp detected during colonoscopy is to remove them and send for histopathology to determine the subsequent surveillance interval. More than 80% of polyps detected during screening or surveillance colonoscopy are diminutive (≤5mm). As the chance of diminutive polyps to harbor cancer or advanced neoplasia is low, leave-in-situ and resect-and-discard strategies using optical diagnosis are recommended for non-neoplastic polyps by the American Society for Gastrointestinal Endoscopy (ASGE) and the European Society for Gastrointestinal Endoscopy (ESGE) so as to reduce the financial burden of polypectomy and histopathology. The societies proposed leave-in-situ strategy if optical diagnosis can achieve a negative predictive value (NPV) of >90% for rectosigmoid polyp and resect-and-discard if an agreement of more than 90% concordance with histopathology-based post-polypectomy surveillance interval can be achieved. However, optical diagnosis is operator dependent and most endoscopists are reluctant to adopt this strategy in routine practice because of the need of strict training and auditing and fear of incorrect diagnosis.
In the past decade, with the exponential increase in computational power, reduced cost of data storage, improved algorithmic sophistication, and increased availability of electronic health data, artificial intelligence (AI) assisted technologies were widely adopted in various healthcare settings to improve clinical outcomes, especially the quality of colonoscopy in the area of gastroenterology. Real time use of computer-aided diagnosis (CADx) for adenoma using AI systems were developed and proven to be useful to help endoscopists to distinguish neoplastic polyps from non-adenomatous polyps. However, these studies only examined diminutive polyp but not polyp of larger size (>5mm). They were conducted with small sample size of less than few hundred subjects and the study settings were open-label and non-randomized.
The investigators aim to conduct a large scale randomized controlled trial to evaluate the performance of colorectal polyp characterization of all size polyps by real-time CADx using AI system against conventional colonoscopy with optical diagnosis.
Detailed description
Study setting
This is an international, prospective, multi-centre, single-blind, non-inferiority, randomized controlled trial conducted in 6 university-affiliated endoscopy centres China (4 centres), Hong Kong and Singapore. This study will be conducted according to the CONSORT-AI and SPIRIT-AI guideline and complied with ICH-GCP and the declaration of Helsinki.
Artificial intelligence polyp characterization system
The investigators refer to the NICE (Narrow Band Imaging International Colorectal Endoscopic) classification as the standard to establish a deep neural network model for polyp type differentiation. To build the polyp characterization model, the investigators collected 3762 images of polyps under NBI for model training and testing, including 1483 cases of hyperplastic polyps, 1993 cases of adenomas and 286 cases of advanced tumors.
The difference of image features among the three types of NICE classification is obvious, and it is easy to distinguish them by computer under endoscope. Considering the processing capacity of the computer hardware equipped with the model, in order to achieve real-time analysis under limited computing resources, the investigators chose a lightweight network architecture called Mobile-Net to build the model. In a Mobile-Net framework, the first is a 3x3 standard convolution layer, followed by a heap of depth-wise separable convolution layers. Some of the depth-wise convolution layers will be down sampled through streets set as 2. The following average pooling layer changes the features to 1x1. According to the predicted category size, a full connection layer is then added, and finally a soft-max layer is added. If the depth-wise convolution layers and point-wise convolution layers are calculated separately, the entire network has only 28 layers ( Avg Pool and Softmax are not included). At present, the model has not been clinically validated. The investigators used a five-fold cross validation to evaluate the accuracy of the model. The results showed that the classification accuracy of the model in the current dataset exceeds 99%
Standardized training of optical diagnosis
Before the initiation of the study, participating endoscopists will be given a standardized online training workshop on the operation of the AI polyp characterization system, principles of optical diagnosis and an image-based quiz.
Colonoscopy procedures
Study colonoscopies will be performed by 12 non-expert endoscopists (colonoscopy experience <2000) and 12 expert endoscopists (colonoscopy experience ≥2000), with 2 non-expert and 2 expert endoscopists from each of the 6 centres. All colonoscopies will be performed by using high-definition endoscopy system and colonoscope (EVIS Lucera Elite, 290 series, Olympus, Co Ltd, Tokyo, Japan). All enrolled patients received low-fiber diets 3 days prior to colonoscopy and underwent bowel cleansing with polyethylene glycol solution in split dose based on institutional protocol. Colonoscopies will be performed under conscious sedation. Bowel preparation quality will be rated by the Boston Bowel Preparation Scale (BBPS) with adequate bowel preparation being defined as BBPS score ≥6 and any segmental BBPS score ≥2.
For patients randomized to the conventional colonoscopy (CC) with optical diagnosis group, the endoscopists will turn on narrow band imaging (NBI) mode once a polyp is detected. An optical diagnosis will be provided without magnification. Hyperplastic and sessile serrated polyps are categorized as non-neoplastic, adenoma and malignancy as neoplastic. The diagnosis will be recorded with the level of confidence of the assessment (high or low). For patients randomized to the AI-powered CADx colonoscopy (AI) group, endoscopists will turn on CADx upon detection of colorectal polyp. The polyp will then be marked by a blue tracking box and shown on the same high-definition monitor of the endoscopy system. The AI will provide a diagnosis (non-neoplastic or neoplastic) next to the tracking box. For the purpose of this study, all polyps irrespective of optical or AI diagnosis will be removed by endoscopic polypectomy/endoscopic mucosal resection (EMR)/endoscopic submucosal dissection (ESD) during withdrawal phrase and send for histopathology. Endoscopists are not allowed to leave any identified polyp in-situ at their discretion.
Location, size and morphology of all removed polyps will be documented. Proximal colon is defined as segment from cecum to transverse colon, while distal colon is defined as segment from splenic flexure to rectum. Polyps will be classified into pedunculated or non-pedunculated morphology and non-pedunculated lesions will be further characterized as sessile, flat or depressed lesions. Polyps removed will be placed in separate specimen bottles. Colonic polyp specimens will be evaluated by pathologists of individual study centre who are blinded to study group assignment. Colonic polyp specimens will be evaluated according to the 2019 WHO classification of tumours of the digestive system. Advanced adenomas are defined as adenomas with size ≥10mm, villous component, or high-grade dysplasia. Diagnostic yield of any existing colonic pathology will not be comprised if the subject is allocated to the AI group. Patients will be monitored for any immediate adverse event post colonoscopy and will be discharged after recovery from sedation.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AI arm | Experimental | Procedure: AI-powered computer-aided diagnosis (CADx)AI will be used to diagnose polyps |
| Control arm | No intervention | –Conventional colonoscopy without AI will be perform to diagnose polyps |
Who may qualify
- Ages
- 40 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- undergoing elective colonoscopy with any indication (screening, surveillance or diagnostic) and complete colonoscopy (caecal intubation) with at least one colorectal polyp detected will be recruited
Key exclusion criteria (2 listed)
- personal history of CRC or inflammatory bowel disease, prior colorectal surgery, receiving anticoagulant therapy
- lack of informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-powered computer-aided diagnosis (CADx)Real time AI will be used to diagnosis polyps found during colonoscopy. | Procedure or surgery | AI arm |
Primary outcome
diagnostic accuracy of polyp histology in %
Time frame: 24 months
the NICE classification (NICE I: non-neoplastic polyp: NICE II: adenoma; NICE III: invasive tumor) given by the AI CADx and conventional optical diagnosis will be compared against the polyp histopathology (reference standard)
5 secondary outcomes
sensitivity (%)
Time frame: 24 months
specificity (%)
Time frame: 24 months
positive predictive value (%)
Time frame: 24 months
negative predictive value (%)
Time frame: 24 months
agreement in assigning post-polypectomy surveillance intervals with pathology-based diagnoses (%)
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Colonic Polyp
Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Recruiting
Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology
Colonic Neoplasms
RecruitingObservational study
KLF4 Epigenetic Modulation
KLF4 Methylation, Epigenetic
RecruitingObservational study
Malignant Polyp Registry
Malignant Colorectal Polyp, Colorectal Cancer
Active, not recruiting
Virtual Incision Robotically Assisted Surgical Device Use in Minimally Invasive Colectomy
Colon Cancer, Colon Polyp
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-powered computer-aided diagnosis (CADx) in people with Colonic Polyp, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
diagnostic accuracy of polyp histology in % (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.